Department of Physiology and Biophysics, University of Mississippi Medical Center , Jackson, Mississippi.
Department of Medicine, University of Mississippi Medical Center , Jackson, Mississippi.
Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F747-F751. doi: 10.1152/ajprenal.00617.2017. Epub 2018 Feb 14.
Renovascular disease (RVD), which is prevalent in the elderly, significantly increases cardiovascular risk and can progressively deteriorate renal function. The loss of renal function in patients with RVD is associated with a progressive dysfunction, damage, and loss of renal microvessels, which can be combined with decreased renal bioavailability of vascular endothelial growth factor (VEGF) and a defective vascular repair and proliferation. This association has been the impetus for recent efforts that have focused on developing methods to stop the progression of renal injury by protecting the renal microvasculature. This mini-review focuses on recent studies supporting potential applications of VEGF therapy for the kidney and discusses underlying mechanisms of renoprotection.
肾血管疾病（RVD）在老年人中较为常见，会显著增加心血管风险，并可使肾功能逐渐恶化。RVD 患者的肾功能丧失与肾微血管的进行性功能障碍、损伤和丧失有关，这可能与肾脏中血管内皮生长因子（VEGF）的生物利用度降低以及血管修复和增殖功能缺陷有关。这种关联促使人们最近努力开发通过保护肾微血管来阻止肾损伤进展的方法。这篇迷你综述重点介绍了支持 VEGF 治疗肾脏的潜在应用的最新研究，并讨论了肾保护的潜在机制。
